A clinical formulation indicated for HIV. Targeted inhibition of viral enzymes assists in maintaining low viral loads to promote better long-term immunity.
Utilized to manage HIV-1 infections by addressing viral replication to support immune health and mitigate the risk of disease progression in adults and children.
Mechanism of Action
Dolutegravir blocks integrase, an enzyme that the HIV virus needs to insert its genetic material into human DNA. By preventing this integration, the drug stops the virus from replicating and spreading inside the body.
Route of Administration
Oral
Onset Time
Steady state in 5 days
Duration
24 hours
Contraindications
Concurrent use with dofetilide, Hypersensitivity to dolutegravir
Severe Adverse Events
Severe liver injury, Hepatitis B reactivation, Severe hypersensitivity reactions, Neural tube defects (potential fetal warning), Depression
Common Side Effects
Headache, Mild fatigue
Uncommon Side Effects
Insomnia, Nausea, Diarrhea, Dizziness, Rash
Drug Interactions
Dofetilide, Metformin, Rifampin, Calcium/Iron supplements, St. John's Wort, Phenytoin
Pregnancy Safety Warnings
Use with caution; discuss potential neural tube defect risks with a physician.
Age Restrictions
Approved for patients weighing at least 3 kg (specific formulations).
Information for Tivicay is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
